课题基金 / 基金详情

Cancer specific and organ-avoiding RNA architectures for quantitative imaging

Cancer specific and organ-avoiding RNA architectures for quantitative imaging
用于定量成像的癌症特异性和器官回避 RNA 结构
批准号:
9208386
负责人:
Bernard Mark Evers
金额:
$29.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2018-06-30

项目摘要

项目成果

Bernard Mark Evers的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Development of image-guided drug delivery systems for real-time monitoring, quantifying and validating the delivery and therapeutic action is very important for both research and clinical applications. Various multifunctional nanoparticles of different materials have been investigated over the last decade as prospective imaging and therapeutic platforms; however, effective strategies to quantitatively evaluate delivery of therapeutic payloads to tumors and metastatic cancer cells in vivo are challenging due to low efficiency in specific cancer targeting and non-specific trapping in vital organs such as, liver an lungs. Our goal is to adopt an innovative RNA nanotechnology approach to construct ultrastable multifunctional RNA Beacons and RNA Dendrimers as image-guided agents for quantitative real-time assessment of tumor and metastatic cancer targeted therapeutic delivery, distribution, uptake and response. We have shown that our RNA nanoparticles are non-toxic, non-immunogenic and capable of penetrating across heterogeneous biological barriers to deliver high doses of therapeutics specifically to solid tumors and metastatic cells in mice with little accumulation in normal organs. This provides an ideal platform for non-invasive imaging of cancer therapeutics in vivo. Our multifunctional RNA nanoparticles will be designed to harbor: (1) imaging modules: NIR fluorophores for in vivo fluorescence imaging; radionuclides for PET/SPECT imaging; and gadolinium contrast agents for MRI; (2) targeting modules: such as RNA aptamers or chemical ligands for binding to cancer specific cell surface receptors resulting in internalization of RNA nanoparticles into cancer cells; and (3) therapeutic modules: siRNAs and anti-miRNA to silence the expression of oncogenic genes. The multifunctional RNA constructs will then be evaluated in our well established colon cancer animal models. We will employ multimodal imaging techniques (NIRF, PET/SPECT and/or MRI) for monitoring the therapeutic delivery process in real-time at various spatial and temporal resolution scales. This approach is based on the consideration that each of the three imaging modalities has advantages, and an integrated approach will lead to synergistic benefits with regards to image-guided therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Immunosuppressive Tumor Microenvironment for Colorectal Cancer Treatment
  • 批准号:
    10748123
  • 项目类别:
  • 资助金额:
    $40.03万
  • 财政年份:
    2023
  • 负责人:
    Bernard Mark Evers
  • 依托单位:
Appalachian Career Training in Oncology (ACTION) Program
  • 批准号:
    10001327
  • 项目类别:
  • 资助金额:
    $45.04万
  • 财政年份:
    2018
  • 负责人:
    Bernard Mark Evers
  • 依托单位:
Appalachian Career Training in Oncology (ACTION) Program
  • 批准号:
    10245140
  • 项目类别:
  • 资助金额:
    $45.98万
  • 财政年份:
    2018
  • 负责人:
    Bernard Mark Evers
  • 依托单位:
Appalachian Career Training in Oncology (ACTION) Program
  • 批准号:
    10475257
  • 项目类别:
  • 资助金额:
    $45.98万
  • 财政年份:
    2018
  • 负责人:
    Bernard Mark Evers
  • 依托单位:
国内基金
海外基金
新生儿坏死性小肠结肠炎中去泛素化酶USP15调控ILC3分化损伤肠道粘膜屏障的致病机制研究
  • 批准号:
    82371711
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    吕志宝
  • 依托单位:
人巨细胞病毒编码蛋白UL23调控 HCMV-specific T 细胞增殖、活性及分化的机理
  • 批准号:
    32070149
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    李弘剑
  • 依托单位:
花胶鱼类物种Species-specific PCR和Multiplex PCR鉴定体系研究
  • 批准号:
    31902373
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2019
  • 负责人:
    曾玲
  • 依托单位:
Dravet综合征基因突变分析及突变来源研究
  • 批准号:
    81171221
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2011
  • 负责人:
    张月华
  • 依托单位: